Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference32 articles.
1. ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards;Bestvina;Lancet Oncol.,2017
2. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer;Wolf;ESMO Open.,2022
3. FLAURA Investigators, Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC;Ramalingam;N. Engl. J. Med.,2020
4. Understanding and targeting resistance mechanisms in NSCLC;Rotow;Nat. Rev. Cancer.,2017
5. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2012
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study);Current Oncology;2024-07-30
2. Lung adenocarcinoma patients with ROS1-rearranged tumors by sex and smoking intensity;Heliyon;2024-04
3. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial;ESMO Open;2024-02
4. Molecular Testing in Lung Cancer;Surgical Pathology Clinics;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3